Form 4: TG Therapeutics Director Sagar Lonial Sells 5,000 Shares
SEC Form 4
Director Sagar Lonial sold 5,000 shares of TG Therapeutics (TGTX) common stock at a price of $15.935 on March 13, 2024.
Summary
- On March 13, 2024, Sagar Lonial, a director of TG Therapeutics, Inc. (TGTX), sold 5,000 shares of common stock.
- The transaction was executed at a price of $15.935 per share.
- Following the transaction, Lonial directly owns 108,878 shares of TG Therapeutics common stock, including restricted shares that vest over time.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to an insider stock sale. It doesn't inherently convey positive or negative sentiment, but the market may interpret the sale based on their own analysis.
Industry Context
Form 4 filings are standard disclosures required by the SEC when corporate insiders (officers, directors, or those holding more than 10% of a company's shares) buy or sell their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's valuation and future prospects. However, insider sales don't always indicate a negative outlook, as they can be motivated by personal financial planning needs.
Stakeholder Impact
- Shareholders may react to the news of the director's stock sale, potentially influencing the stock price.
Key Dates
| Date | Description |
|---|---|
| 03/13/2024 | Date of the transaction: Sagar Lonial sold 5,000 shares of TGTX. |
| 03/15/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.